Intrinsic sympathomimetic activity: Difference between revisions
Jump to navigation
Jump to search
m Protected "Intrinsic sympathomimetic activity": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
{{ | {{SK}} ISA | ||
==Overview== | |||
Some beta blockers (e.g. [[oxprenolol]], [[pindolol]], [[penbutolol]] and [[acebutolol]]) exhibit intrinsic sympathomimetic activity (ISA). These agents are capable of exerting low level [[receptor agonist|agonist]] activity at the β-adrenergic receptor while simultaneously acting as a receptor site [[receptor antagonist|antagonist]]. These agents, therefore, may be useful in individuals exhibiting excessive [[bradycardia]] with sustained beta blocker therapy. | Some beta blockers (e.g. [[oxprenolol]], [[pindolol]], [[penbutolol]] and [[acebutolol]]) exhibit intrinsic sympathomimetic activity (ISA). These agents are capable of exerting low level [[receptor agonist|agonist]] activity at the β-adrenergic receptor while simultaneously acting as a receptor site [[receptor antagonist|antagonist]]. These agents, therefore, may be useful in individuals exhibiting excessive [[bradycardia]] with sustained beta blocker therapy. | ||
| Line 12: | Line 14: | ||
<references/> | <references/> | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 22:41, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: ISA
Overview
Some beta blockers (e.g. oxprenolol, pindolol, penbutolol and acebutolol) exhibit intrinsic sympathomimetic activity (ISA). These agents are capable of exerting low level agonist activity at the β-adrenergic receptor while simultaneously acting as a receptor site antagonist. These agents, therefore, may be useful in individuals exhibiting excessive bradycardia with sustained beta blocker therapy.
Agents with ISA are not used in post-myocardial infarction as they have not been demonstrated to be beneficial. They may also be less effective than other beta blockers in the management of angina and tachyarrhythmia.[1]
References
- ↑ Editor Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook.